Adcomm Debates Clinical Data vs. Personal Data in Decision Not to Approve ALS Stem Cell Therapy

Despite strong testimony and comments from patients and clinicians, the FDA advisory committee reviewing NurOwn, an investigational treatment for amyotrophic lateral sclerosis (ALS), voted against recommending the drug, citing a lack of consistent data and ill-defined biomarkers.
Source: Drug Industry Daily